Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.41 |
| ▸ | CX3CR1 | P49238 | 14/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022728 | 0.81 | CXCR2 (0.52) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL213688 | 0.81 | CXCR2 (0.52) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL213689 | 0.81 | CXCR2 (0.52) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL2019579 | 0.75 | CXCR2 (0.39) | CXCR2CX3CR1 | |
| SCHEMBL5436823 | 0.71 | CXCR2 (0.76) | CXCR2CX3CR1 | |
| SCHEMBL213960 | 0.69 | CX3CR1 (0.54) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL12022709 | 0.69 | CX3CR1 (0.54) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL211982 | 0.68 | CXCR2 (0.64) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL12022742 | 0.67 | CXCR2 (0.53) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL215490 | 0.67 | CXCR2 (0.53) | CXCR2CX3CR1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960395-B2 | 5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20080318981-A1 | Novel Compounds 480 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318981-A1 | Novel Compounds 480 | CX3CR1, CCR2, CXCR3 | CXCR2 6/4885CX3CR1 1/4885ADORA1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.